BrainsWay Presents New Prospective 12-Month Durability Data Demonstrating Sustained Clinical Benefits Following Accelerated Deep Transcranial Magnetic Stimulation For Major Depressive Disorder

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the presentation of new prospective 12-month durability data demonstrating sustained clinical benefits following accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Major Depressive Disorder (MDD).

The findings were recently presented in a poster by Colleen Hanlon, PhD, Vice President of Medical Affairs for BrainsWay, at the 14th Annual Clinical TMS Society (CTMSS) Meeting which was held on June 4-6, 2026. The data represented outcomes from the first multisite, randomized, controlled trial evaluating the long-term outcomes of BrainsWay's SWIFT™ protocol, an FDA-cleared Deep TMS protocol which reduces the number of clinic visits in the acute phase by 70% in comparison to the traditional standard protocol.